LCTX · XBRL financial data

Lineage Cell Therapeutics financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LCTX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	1,826	4,341	14,703	8,945	9,499	14,556
Revenue from contracts with customers	1,826	4,341	14,703	8,945	9,499	14,556
Cost of revenue	385	1,426	728	671	334	—
Gross profit	1,441	2,915	13,975	8,274	—	—
Research and development	12,317	33,914	13,987	15,705	12,472	17,729
General and administrative	15,571	18,212	22,508	17,302	18,171	18,460
Total operating expenses	27,888	52,126	36,495	33,007	—	—
Other operating income (expense)	44	—	—	—	—	—
Operating income (loss)	(26,447)	(49,211)	(22,520)	(24,733)	(21,478)	(36,619)
Other income (expense)	2,880	1,486	(2,152)	(4)	(670)	(132)
Income tax expense (benefit)	(1,239)	—	541	(1,803)	0	(5,280)
Net income (loss)	(20,649)	(43,019)	(26,273)	(21,486)	(18,609)	(63,533)
Earnings per share, basic USD per share	—	(0.26)	(0.15)	(0.12)	(0.09)	(0.28)
Earnings per share, diluted USD per share	—	—	(0.15)	(0.12)	(0.09)	(0.28)
Weighted average shares, basic thousands of shares	—	164,502	169,792	172,663	200,193	230,116
Weighted average shares, diluted thousands of shares	—	—	169,792	172,663	200,193	230,116

Fiscal years (LCTX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	32,585	55,742	11,355	35,442	45,789	40,791
Marketable securities	8,977	2,616	46,520	50	2,016	14,990
Accounts receivable	—	50,600	297	745	638	891
Prepaid and other current assets	2,433	2,351	1,828	2,204	2,554	2,485
Total current assets	43,999	111,549	60,000	38,441	50,997	59,157
Property and equipment, net	5,630	4,872	5,673	4,767	2,251	2,566
Right-of-use asset	215	—	—	2,522	2,144	2,131
Goodwill	10,672	10,672	10,672	10,672	10,672	10,672
Total assets	107,949	174,545	123,664	101,019	113,218	112,584
Accounts payable	2,611	3,543	2,393	2,050	1,174	2,341
Accrued liabilities	1,711	22,086	3,833	1,097	1,197	1,096
Total current liabilities	7,769	47,116	18,981	17,960	13,977	11,367
Lease liability, non-current	2,514	1,941	2,860	1,979	1,295	1,534
Total liabilities	12,822	83,647	51,728	38,996	36,206	69,238
Accumulated deficit	(294,078)	(337,097)	(363,370)	(384,856)	(403,465)	(466,998)
Total stockholders' equity	96,199	92,221	73,339	63,419	78,381	44,549
Total liabilities and equity	107,949	174,545	123,664	101,019	113,218	112,584
Common shares outstanding (cover page) thousands of shares	161,638	169,709	170,146	188,534	228,356	249,088

Fiscal years (LCTX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(20,649)	(43,019)	(26,273)	(21,486)	(18,609)	(63,533)
Stock-based compensation	2,227	3,519	4,287	4,640	5,077	4,752
Depreciation and amortization	823	663	582	—	—	—
Net cash from operating activities	(19,753)	(23,561)	1,059	(28,566)	(23,092)	(18,919)
Purchases of property and equipment	64	354	413	674	565	522
Net cash from investing activities	13,038	9,745	(46,159)	46,449	(2,308)	(13,457)
Proceeds from issuing common stock	5,127	30,865	148	6,625	—	—
Net cash from financing activities	29,865	36,930	1,632	6,423	35,857	26,950
Net change in cash	23,087	23,094	(44,341)	24,056	10,362	(5,030)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Lineage Cell Therapeutics	37,355	1,069	(7,244)*	252.9M	7.0 quarters	Q2 FY26 10-QJun 30, 2026
Forte Biosciences	49,629	not reported	(22,702)*	21.2M	8.7 quarters	Q2 FY26 10-QJun 30, 2026
4D Molecular Therapeutics	70,372	3,781	(69,999)*	55.2M	5.2 quarters	Q2 FY26 10-QJun 30, 2026
Monopar Therapeutics	52,758	0*	(3,247)*	6.7M	32.4 quarters	Q2 FY26 10-QJun 30, 2026
XOMA Royalty	85,600	12,318	6,121	12.5M	—	Q1 FY26 10-QMar 31, 2026
Lexicon Pharmaceuticals	40,924	692	(9,192)*	445.0M	20.7 quarters	Q2 FY26 10-QJun 30, 2026
Sangamo Therapeutics	27,586	1,442	(19,282)	414.3M	1.4 quarters	Q1 FY26 10-QMar 31, 2026
Omeros	1,988	28,529	4,149*	72.4M	—	Q2 FY26 10-QJun 30, 2026
Alpha Cognition	41,384	6,093	(6,859)*	21.8M	6.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.